CoChat

Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases

Open access

The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.

Abstract

Compound heterozygous recessive or polygenic diseases could be addressed through gene correction of multiple alleles. However, targeting of multiple alleles using genome editors could lead to mixed genotypes and adverse events that amplify during tissue morphogenesis. Here we demonstrate that Cas9-ribonucleoprotein-based genome editors can correct two distinct mutant alleles within a single human cell precisely. Gene-corrected cells in an induced pluripotent stem cell model of Pompe disease expressed the corrected transcript from both corrected alleles, leading to enzymatic cross-correction of diseased cells. Using a quantitative in silico model for the in vivo delivery of genome editors into the developing human infant liver, we identify progenitor targeting, delivery efficiencies, and suppression of imprecise editing outcomes at the on-target site as key design parameters that control the efficacy of various therapeutic strategies. This work establishes that precise gene editing to correct multiple distinct gene variants could be highly efficacious if designed appropriately.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-20065-8

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A combined in vitro and in silico strategy to evaluate the efficacy of different gene correction therapeutic strategies. a Schematic indicating the modeling approach in which samples from patients are collected ex vivo are then genome-edited in vitro. Genotypes and phenotype outcomes from the in vitro studies are inputs for an in silico model that simulates the delivery of the therapeutic in vivo as well as tissue morphogenesis (GETEM model, Fig. 5). The results of the in silico model can ultimately guide dosing and formulation decisions. b Editing strategy for gene correction of Pompe-diseased induced pluripotent stem cells (iPSCs). Pompe disease is caused by two defective copies of the acid-α-glucosidase (GAA) gene. This enzyme is responsible for breakdown of glycogen within lysosomes inside cells. Without GAA, glycogen build up can cause downstream health issues. After correction, GAA expresses a functional protein leading to a reduction in glycogen. The schematic indicates the editing locations within GAA locus and CRISPR gene correction strategy. In the Pompe patient-derived line, cells harbor compound heterozygous mutations in GAA. Allele one, a1, contains a point mutation that causes a premature stop codon (GAA:c.[1441=2237G>A]) while allele two, a2, carries a one base pair deletion (GAA:c.[1441delT;2237=]). For the CRISPR gene correction strategy, single guide RNAs (sgRNAs; the predicted DNA double-strand break by SpyCas9 is denoted by the arrowhead) were designed to be specific to only the diseased allele by containing the mutant bases (red) within the seed region. Single-stranded oligonucleotides (ssODNs) used for genomic repair contained the wildtype sequence at the mutation site (blue) as well as a silent mutation “wobble” to remove the PAM site (green) to prevent re-cutting of the corrected allele while preserving the amino acid sequence of GAA.
Fig. 1 A combined in vitro and in silico strategy to evaluate the efficacy of different gene correction therapeutic strategies. a Schematic indicating the modeling approach in which samples from patients are collected ex vivo are then genome-edited in vitro. Genotypes and phenotype outcomes from the in vitro studies are inputs for an in silico model that simulates the delivery of the therapeutic in vivo as well as tissue morphogenesis (GETEM model, Fig. 5). The results of the in silico model can ultimately guide dosing and formulation decisions. b Editing strategy for gene correction of Pompe-diseased induced pluripotent stem cells (iPSCs). Pompe disease is caused by two defective copies of the acid-α-glucosidase (GAA) gene. This enzyme is responsible for breakdown of glycogen within lysosomes inside cells. Without GAA, glycogen build up can cause downstream health issues. After correction, GAA expresses a functional protein leading to a reduction in glycogen. The schematic indicates the editing locations within GAA locus and CRISPR gene correction strategy. In the Pompe patient-derived line, cells harbor compound heterozygous mutations in GAA. Allele one, a1, contains a point mutation that causes a premature stop codon (GAA:c.[1441=2237G>A]) while allele two, a2, carries a one base pair deletion (GAA:c.[1441delT;2237=]). For the CRISPR gene correction strategy, single guide RNAs (sgRNAs; the predicted DNA double-strand break by SpyCas9 is denoted by the arrowhead) were designed to be specific to only the diseased allele by containing the mutant bases (red) within the seed region. Single-stranded oligonucleotides (ssODNs) used for genomic repair contained the wildtype sequence at the mutation site (blue) as well as a silent mutation “wobble” to remove the PAM site (green) to prevent re-cutting of the corrected allele while preserving the amino acid sequence of GAA.CC BY · PubMed Central
Fig. 2 Gene correction of two distinct mutant alleles within a single human cell. a ArrayEdit-based isolation of iPSC clones corrected at either or both loci. CRISPR S1mplex design for the gene correction of compound heterozygous mutations. S1mplexes targeting 1441delT mutant were labeled with an AlexaFluor488 compound while S1mplexes targeting the 2237G>A mutation were labeled with an AlexaFluor647. These ribonucleoprotein genome editors were mixed prior to transfecting into cells and subsequently plated on the ArrayEdit platform to conduct high-content analysis (see Supplementary Fig. 1). b Left: LysoSensor quantification per µFeature of two mock transfections after 7 days of growth. Normal control hPSCs were significantly more intense than unedited, Pompe diseased iPSCs on ArrayEdit. Bottom right: the growth rate of unedited and control hPSCs following a mock transfection to establish a baseline for growth. Growth rates were calculated by measuring the per-day change in the number of cells of the µFeature. Top right: LysoSensor intensity was plotted against growth rate per µFeature to identify edited colonies. Dashed lines indicate regions of interest. (n = 145 independent cell lines). c Magnification of quadrant II from (b). µFeatures in this region were selected for genomic analysis to isolate edited clones. (n = 17 independent cell lines). d Sanger sequencing traces of corrected cell lines. The unedited line contains mutations at both alleles: 1441delT mutation causes a breakdown of sequence trace, whereas a single point mutation demonstrates a heterozygosity 2237G>A locus. SpyCas9 cut site is denoted by a dotted line. e Karyotypes of all isolated gene-corrected lines as well as unedited cells. No abnormalities were detected at a band resolution of 500. f Immunocytochemistry of pluripotency markers in gene-corrected lines. All lines were positive for pluripotency markers NANOG and TRA-1-60 (scale bar: 100 µm). g Schematic of long PCR covering both SpyCas9 cut sites. Arrows denote primers. The expected PCR amplicon is 7959 bp in length. h Gel analysis of long-range PCR described in (g) in each isolated cell line. No significant deviances from the expected length were detected, and no other notable bands were observed. WA09 control cells are hPSCs.
Fig. 2 Gene correction of two distinct mutant alleles within a single human cell. a ArrayEdit-based isolation of iPSC clones corrected at either or both loci. CRISPR S1mplex design for the gene correction of compound heterozygous mutations. S1mplexes targeting 1441delT mutant were labeled with an AlexaFluor488 compound while S1mplexes targeting the 2237G>A mutation were labeled with an AlexaFluor647. These ribonucleoprotein genome editors were mixed prior to transfecting into cells and subsequently plated on the ArrayEdit platform to conduct high-content analysis (see Supplementary Fig. 1). b Left: LysoSensor quantification per µFeature of two mock transfections after 7 days of growth. Normal control hPSCs were significantly more intense than unedited, Pompe diseased iPSCs on ArrayEdit. Bottom right: the growth rate of unedited and control hPSCs following a mock transfection to establish a baseline for growth. Growth rates were calculated by measuring the per-day change in the number of cells of the µFeature. Top right: LysoSensor intensity was plotted against growth rate per µFeature to identify edited colonies. Dashed lines indicate regions of interest. (n = 145 independent cell lines). c Magnification of quadrant II from (b). µFeatures in this region were selected for genomic analysis to isolate edited clones. (n = 17 independent cell lines). d Sanger sequencing traces of corrected cell lines. The unedited line contains mutations at both alleles: 1441delT mutation causes a breakdown of sequence trace, whereas a single point mutation demonstrates a heterozygosity 2237G>A locus. SpyCas9 cut site is denoted by a dotted line. e Karyotypes of all isolated gene-corrected lines as well as unedited cells. No abnormalities were detected at a band resolution of 500. f Immunocytochemistry of pluripotency markers in gene-corrected lines. All lines were positive for pluripotency markers NANOG and TRA-1-60 (scale bar: 100 µm). g Schematic of long PCR covering both SpyCas9 cut sites. Arrows denote primers. The expected PCR amplicon is 7959 bp in length. h Gel analysis of long-range PCR described in (g) in each isolated cell line. No significant deviances from the expected length were detected, and no other notable bands were observed. WA09 control cells are hPSCs.CC BY · PubMed Central
Fig. 3 Transcription and protein levels within gene-corrected cells. a Schematic indicating the genotypes of the iPSC lines generated and mRNA transcripts collected. Deep sequencing from qRT-PCR around both diseased loci in isolated cell lines. Reads were classified as WT, mutant, or corrected (PAM wobble) and mapped to either allele 1 (top bar) or allele 2 (bottom bar). When neither allele was corrected, both alleles were expressed at approximately the same rate. However, when either mutation was corrected, the corresponding allele was expressed at a higher rate than the one that still possessed a mutation. When both alleles were corrected, the fraction of reads making up the population was evenly distributed. Observations at individual alleles were consistent across both assayed loci. b Western blot for GAA protein. Each of the corrected lines expressed high levels of active protein as well as detectable levels of the precursor protein. Unedited cells expressed significantly lower levels of GAA protein, but the level was still above the limit of detection. c GAA activity in cell lysate as measured by 4-MUG cleavage in acidic conditions. Unedited cells have significantly lower activity showing there was little to no active protein. Corrected cell lines include Double Correct.c1 (isolated via ArrayEdit), Double Correct.c21, Double Correct.c28, Double Correct.c29, Double Correct.c30 (isolated via sequential correction of 2237G>A allele followed by S1mplex electroporation correction of 1440delT) and Double Correct.c73 (isolated via sequential correction of 2237G>A allele followed by using transient puromycin based correction of 1440delT). All corrected lines had significantly higher activity than unedited cells but were indistinguishable from each other (n = 5 technical replicates, ****p = 3.59 × 10−12, two-tailed t-test, α = 0.05, heteroscedastic; mean ± s.d).
Fig. 3 Transcription and protein levels within gene-corrected cells. a Schematic indicating the genotypes of the iPSC lines generated and mRNA transcripts collected. Deep sequencing from qRT-PCR around both diseased loci in isolated cell lines. Reads were classified as WT, mutant, or corrected (PAM wobble) and mapped to either allele 1 (top bar) or allele 2 (bottom bar). When neither allele was corrected, both alleles were expressed at approximately the same rate. However, when either mutation was corrected, the corresponding allele was expressed at a higher rate than the one that still possessed a mutation. When both alleles were corrected, the fraction of reads making up the population was evenly distributed. Observations at individual alleles were consistent across both assayed loci. b Western blot for GAA protein. Each of the corrected lines expressed high levels of active protein as well as detectable levels of the precursor protein. Unedited cells expressed significantly lower levels of GAA protein, but the level was still above the limit of detection. c GAA activity in cell lysate as measured by 4-MUG cleavage in acidic conditions. Unedited cells have significantly lower activity showing there was little to no active protein. Corrected cell lines include Double Correct.c1 (isolated via ArrayEdit), Double Correct.c21, Double Correct.c28, Double Correct.c29, Double Correct.c30 (isolated via sequential correction of 2237G>A allele followed by S1mplex electroporation correction of 1440delT) and Double Correct.c73 (isolated via sequential correction of 2237G>A allele followed by using transient puromycin based correction of 1440delT). All corrected lines had significantly higher activity than unedited cells but were indistinguishable from each other (n = 5 technical replicates, ****p = 3.59 × 10−12, two-tailed t-test, α = 0.05, heteroscedastic; mean ± s.d).CC BY · PubMed Central
Fig. 4 Enzymatic cross-correction of unedited cardiomyocytes by gene-corrected cardiomyocytes. a Schematic of enzymatic cross-correction experiments using gene-corrected cardiomyocytes. Unedited iPSC-CMs (red) were supplied media without glucose for 24 h (orange). After 24 h, media was replaced with media (pink) that had previously been exposed to corrected cell lines (blue) or supplemented with rhGAA. 24–96 hours after replacement, unedited cells were stained with LysoSensor and imaged using confocal microscopy for dye intensity. b Quantification of LysoSensor intensity in cross-corrected lines 96 h post media exchange. Each triangle represents a corrected cell identified using CellProfiler. After 96 h of daily media changes or supplementing with rhGAA, all conditions had a significant increase in dye intensity over control conditions. Unedited cells were modified to express histone 2B (H2B)-mCherry to facilitate imaging of the nuclei in these assays. See also Supplementary Fig. 7. (***p < 10−15, n = 262, 201, 261, 249, 135, and 302 independent lysozymes respectively per condition, as detailed in Supplementary Table 7, two-tailed t-test, α = 0.05, heteroscedastic; mean ± s.d). c Representative images of unedited iPSC-CMs stained with LysoSensor in media from unedited and double-corrected iPSC-CMs. d Representative images of LAMP1 staining in unedited, single corrected, double-corrected cells and control PSC-CM and unedited iPSC-CM treated with rhGAA. (scale bars: 10 µm). Select enlarged LAMP1-positive lysosomes are identified by white arrowheads.
Fig. 4 Enzymatic cross-correction of unedited cardiomyocytes by gene-corrected cardiomyocytes. a Schematic of enzymatic cross-correction experiments using gene-corrected cardiomyocytes. Unedited iPSC-CMs (red) were supplied media without glucose for 24 h (orange). After 24 h, media was replaced with media (pink) that had previously been exposed to corrected cell lines (blue) or supplemented with rhGAA. 24–96 hours after replacement, unedited cells were stained with LysoSensor and imaged using confocal microscopy for dye intensity. b Quantification of LysoSensor intensity in cross-corrected lines 96 h post media exchange. Each triangle represents a corrected cell identified using CellProfiler. After 96 h of daily media changes or supplementing with rhGAA, all conditions had a significant increase in dye intensity over control conditions. Unedited cells were modified to express histone 2B (H2B)-mCherry to facilitate imaging of the nuclei in these assays. See also Supplementary Fig. 7. (***p < 10−15, n = 262, 201, 261, 249, 135, and 302 independent lysozymes respectively per condition, as detailed in Supplementary Table 7, two-tailed t-test, α = 0.05, heteroscedastic; mean ± s.d). c Representative images of unedited iPSC-CMs stained with LysoSensor in media from unedited and double-corrected iPSC-CMs. d Representative images of LAMP1 staining in unedited, single corrected, double-corrected cells and control PSC-CM and unedited iPSC-CM treated with rhGAA. (scale bars: 10 µm). Select enlarged LAMP1-positive lysosomes are identified by white arrowheads.CC BY · PubMed Central
Fig. 5 Derivation, empirical training, and validation of in silico gene therapy efficacy model (GETEM) for Pompe disease correction in a developing infant. a Schematic showing enzymatic cross-correction of somatic tissues by injected rhGAA (enzyme replacement therapy, ERT). For a given developing liver of a patient, progenitor cells proliferate and can asymmetrically divide into mature cells. Injected rhGAA is absorbed by the liver as well as striated muscle tissue (both heart and skeletal muscle). b Percentage of normal cardiac tissue within a heart of a Pompe diseased infant after one year of biweekly ERT at 20 mg/kg. Percentages of normal skeletal muscle tissue and hepatocytes are in Supplementary Fig. 9. c Schematic for in silico gene editing model for previously published precise correction of a single base pair in mouse disease models, d Flowchart for training and validating the GETEM model using previously published studies of in vivo somatic cell genome editing of a mouse liver by intravenous injection. e (top) Absolute change of edited cells over time predicted by the GETEM for the studies utilized in (d). For studies that employed selection in the liver, arrows indicate the time at which the selective pressure favoring edited cells was applied (for Fah−/− models, this indicates the removal of NTBC supplementation in the diet; and, for Otc editing, this indicates the induction of a high protein diet.). f Validation of the model using additional published editing strategies. Arrows on days 21 and 24 indicate removal of selection pressure on the treated mice as per published experimental protocol. Arrow on day 2 in the mRNA LNP indicates redosing of the LNP. (n represents biological replicates as previously reported in the literature, mean ± s.d). g Percentage of total sequencing reads from primary fibroblasts of Pompe diseased patients that were treated with S1mplexes targeting W746X D645N or R660H GAA mutations. Results indicate gene correction and imprecise editing for three different mutations. h Percentage of edited alleles that are precisely edited in (g).
Fig. 5 Derivation, empirical training, and validation of in silico gene therapy efficacy model (GETEM) for Pompe disease correction in a developing infant. a Schematic showing enzymatic cross-correction of somatic tissues by injected rhGAA (enzyme replacement therapy, ERT). For a given developing liver of a patient, progenitor cells proliferate and can asymmetrically divide into mature cells. Injected rhGAA is absorbed by the liver as well as striated muscle tissue (both heart and skeletal muscle). b Percentage of normal cardiac tissue within a heart of a Pompe diseased infant after one year of biweekly ERT at 20 mg/kg. Percentages of normal skeletal muscle tissue and hepatocytes are in Supplementary Fig. 9. c Schematic for in silico gene editing model for previously published precise correction of a single base pair in mouse disease models, d Flowchart for training and validating the GETEM model using previously published studies of in vivo somatic cell genome editing of a mouse liver by intravenous injection. e (top) Absolute change of edited cells over time predicted by the GETEM for the studies utilized in (d). For studies that employed selection in the liver, arrows indicate the time at which the selective pressure favoring edited cells was applied (for Fah−/− models, this indicates the removal of NTBC supplementation in the diet; and, for Otc editing, this indicates the induction of a high protein diet.). f Validation of the model using additional published editing strategies. Arrows on days 21 and 24 indicate removal of selection pressure on the treated mice as per published experimental protocol. Arrow on day 2 in the mRNA LNP indicates redosing of the LNP. (n represents biological replicates as previously reported in the literature, mean ± s.d). g Percentage of total sequencing reads from primary fibroblasts of Pompe diseased patients that were treated with S1mplexes targeting W746X D645N or R660H GAA mutations. Results indicate gene correction and imprecise editing for three different mutations. h Percentage of edited alleles that are precisely edited in (g).CC BY · PubMed Central
Fig. 6 In vivo somatic cell gene correction strategies involve tradeoffs between efficiency, precision, progenitor affinity, and editor stability. a In silico Gene Therapy Efficacy Model (GETEM) for Pompe disease correction in a developing infant. Schematic showing gene correction for two diseased alleles in a liver indicating correction of alleles, a1 and a2, by genome editors 1 and 2 to form gene-corrected cells capable of secreting GAA to enzymatically correct other unedited cells. Secreted GAA is also absorbed by striated muscle tissue (both heart and skeletal muscle). b Percentage of normal cardiac tissue within a developing heart of a Pompe diseased infant after the administration of six doses of genome editors at 23.9 mg/kg. c Cell numbers indicating growth of diseased, normal, and precisely-edited cells in the gene-edited liver depot after the administration of 6 doses of genome editors at 23.9 mg/kg. d Distribution of genotypes in the gene-edited liver depot after the administration of 6 doses of genome editors at 23.9 mg/kg. e Sensitivity analysis of the model indicating the absolute values of parameter sensitivity of tissue morphogenesis factors, genome editor factors, and cell/tissue biology intrinsic factors. f Tradeoff between genome editor efficiency and genome editor stability, focusing on the percentage of enzymatically cross-corrected heart tissue. Heatmap indicates that lower efficiency editors could be efficacious if the extracellular editor stability increases. g Tradeoff between genome editor efficiency and precision, focusing on the percentage of enzymatically cross-corrected heart tissue. Heatmap indicates that lower efficiency editors can be efficacious if higher precision editors are used. h Tradeoff between increasing genome editor dose and progenitor affinity, focusing on the percentage of enzymatically cross-corrected heart tissue. i Using GETEM, heatmap indicating tradeoff in heart muscle correction in the developing infant between the degradation rates of GAA in the serum and cellular GAA, indicating that stabilization of GAA in the serum can improve clinical outcome (gray arrowhead indicates pre-stabilization, black arrowhead indicates post-stabilization). Simulation results for liver and skeletal muscle are shown in Supplementary Figs. 11 and 12.
Fig. 6 In vivo somatic cell gene correction strategies involve tradeoffs between efficiency, precision, progenitor affinity, and editor stability. a In silico Gene Therapy Efficacy Model (GETEM) for Pompe disease correction in a developing infant. Schematic showing gene correction for two diseased alleles in a liver indicating correction of alleles, a1 and a2, by genome editors 1 and 2 to form gene-corrected cells capable of secreting GAA to enzymatically correct other unedited cells. Secreted GAA is also absorbed by striated muscle tissue (both heart and skeletal muscle). b Percentage of normal cardiac tissue within a developing heart of a Pompe diseased infant after the administration of six doses of genome editors at 23.9 mg/kg. c Cell numbers indicating growth of diseased, normal, and precisely-edited cells in the gene-edited liver depot after the administration of 6 doses of genome editors at 23.9 mg/kg. d Distribution of genotypes in the gene-edited liver depot after the administration of 6 doses of genome editors at 23.9 mg/kg. e Sensitivity analysis of the model indicating the absolute values of parameter sensitivity of tissue morphogenesis factors, genome editor factors, and cell/tissue biology intrinsic factors. f Tradeoff between genome editor efficiency and genome editor stability, focusing on the percentage of enzymatically cross-corrected heart tissue. Heatmap indicates that lower efficiency editors could be efficacious if the extracellular editor stability increases. g Tradeoff between genome editor efficiency and precision, focusing on the percentage of enzymatically cross-corrected heart tissue. Heatmap indicates that lower efficiency editors can be efficacious if higher precision editors are used. h Tradeoff between increasing genome editor dose and progenitor affinity, focusing on the percentage of enzymatically cross-corrected heart tissue. i Using GETEM, heatmap indicating tradeoff in heart muscle correction in the developing infant between the degradation rates of GAA in the serum and cellular GAA, indicating that stabilization of GAA in the serum can improve clinical outcome (gray arrowhead indicates pre-stabilization, black arrowhead indicates post-stabilization). Simulation results for liver and skeletal muscle are shown in Supplementary Figs. 11 and 12.CC BY · PubMed Central
Fig. 7 Durable gene-corrected cell therapy for Pompe disease requires persistent proliferative cells. a Plots showing the degree of phenotypically normal cardiac tissue when either 10 billion non-proliferative single- or double-corrected cells are dosed or 0.1 billion proliferative single- or double-corrected cells are dosed. For these plots, the GAA production for double-corrected cells is 150% excess that of single corrected cells for four different half-lives of dosed cells. For long-lasting correction, proliferative progenitor cells need to have a half-life exceeding 100 days. b Heatmap showing the proliferative cell dose (assuming double-corrected cells with 75% excess GAA production compared to single-corrected cells) against the half-life of dosed cells. If the dosed cells have a half-life similar to endogenous hepatocytes, a 75 million cell dose is sufficient for matching ERT. c Heatmap showing the proliferative cell dose (assuming that the dosed cells have 250-day half-life) against the GAA production rate of dosed cells, demonstrating that dose has a higher effect on therapeutic efficacy than GAA production gained from double correction. d Heatmap showing that the GAA production against the half-life of the dosed cells (assuming that 250 million cells were dosed), indicating that the half-life of the dosed cells has a higher effect on therapeutic efficacy than the GAA production gained from double correction. e Sensitivity analysis for model parameters relevant to cell therapy. In addition to growth and differentiation rates of the transplanted cells, outcomes are highly sensitive to the proliferative cell half-life, cell dose and excess GAA produced by double gene correction. These later parameters, relevant to the design of therapy with autologous gene-corrected cells, are bolded.
Fig. 7 Durable gene-corrected cell therapy for Pompe disease requires persistent proliferative cells. a Plots showing the degree of phenotypically normal cardiac tissue when either 10 billion non-proliferative single- or double-corrected cells are dosed or 0.1 billion proliferative single- or double-corrected cells are dosed. For these plots, the GAA production for double-corrected cells is 150% excess that of single corrected cells for four different half-lives of dosed cells. For long-lasting correction, proliferative progenitor cells need to have a half-life exceeding 100 days. b Heatmap showing the proliferative cell dose (assuming double-corrected cells with 75% excess GAA production compared to single-corrected cells) against the half-life of dosed cells. If the dosed cells have a half-life similar to endogenous hepatocytes, a 75 million cell dose is sufficient for matching ERT. c Heatmap showing the proliferative cell dose (assuming that the dosed cells have 250-day half-life) against the GAA production rate of dosed cells, demonstrating that dose has a higher effect on therapeutic efficacy than GAA production gained from double correction. d Heatmap showing that the GAA production against the half-life of the dosed cells (assuming that 250 million cells were dosed), indicating that the half-life of the dosed cells has a higher effect on therapeutic efficacy than the GAA production gained from double correction. e Sensitivity analysis for model parameters relevant to cell therapy. In addition to growth and differentiation rates of the transplanted cells, outcomes are highly sensitive to the proliferative cell half-life, cell dose and excess GAA produced by double gene correction. These later parameters, relevant to the design of therapy with autologous gene-corrected cells, are bolded.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 107 references

Cited by

See all 33

Metadata

Authors
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., Goedland, M., Dombroe, M. J., & Saha, K.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
Saha, Krishanu
Venue
Nature Communications
Published
2020-12-08
Volume
11
Issue
1
Pages
6277-6277
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3112830125
Cited by
32
References
108
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 1 · 2021: 18 · 2020: 4
FWCI
2.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (P30CA014520, 1350178, 1645123)
  • University of Wisconsin Carbone Cancer Center (CA014520, P30 CA 014520, Grant P30 CA014520)
  • National Cancer Institute (P30CA014520)
  • National Institute of General Medical Sciences (R35GM119644)
  • Division of Chemical, Bioengineering, Environmental, and Transport Systems
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
polygenic disease, Cas9 ribonucleoprotein, Pompe disease, induced pluripotent stem cells
MeSH terms
Gene Editing, Alleles, Cells, Cultured, Computer Simulation, Glycogen Storage Disease Type II, Humans, Infant, Liver, Male, Models, Genetic, Mutation, Genetic Therapy, Gene Transfer Techniques, Inheritance Patterns, Induced Pluripotent Stem Cells, Primary Cell Culture, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases. https://app.cochat.ai/papers/10.1038/s41467-020-20065-8
The paper
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., Goedland, M., Dombroe, M. J., & Saha, K. (2020). Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases. Nature Communications. https://doi.org/10.1038/s41467-020-20065-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.